Compare Moderna, Inc. (MRNA) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Yum China Holdings Inc — how do they compare? Moderna, Inc. trades at $137.5 (market cap $56.02B), while Yum China Holdings Inc trades at $42.34 (market cap $14.74B). The key difference: Moderna, Inc. is far larger — about 3.8× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays a 2.68% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | YUMC | |
|---|---|---|
Market Cap | $56.02B | $14.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $174.38 | $57.95 |
52-Week Low | $22.36 | $40.18 |
Enterprise Value | $52.17B | $15.65B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
YUMC trades at $43.34, down 0.6% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth, reaching $11.8B in 2025, with a net income margin of 7.84%. Recent developments include the acquisition of Pizza Hut brand ownership in Mainland China and expansion of Pizza Hut Burger Bars to 300 locations.
The outlook is positive with strong analyst support—14 buy ratings and a projected 25.6% upside. Risks include competitive pressures and market volatility, but solid fundamentals and growth initiatives provide a compelling case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
